Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro

Ashland Inc. (ASH) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
while the company maintains a healthy 3.06 current ratio, the extreme volatility in earnings and the $742 million net loss in 2025Q3 suggest that the underlying business transition has yet to achieve the stability required for a clear buy recommendation.
Ashland Inc. (ASH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ashland Inc. (ASH) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.91vs $0.97-6.2% | $482Mvs $486M-0.7% |
| Q1 2026 | Feb 2, 2026 | $0.26vs $0.23+13.0% | $386Mvs $401M-3.7% |
| Q4 2025 | Nov 4, 2025 | $1.08vs $1.17-7.7% | $478Mvs $397M+20.4% |
| Q3 2025 | Jul 29, 2025 | $1.04vs $1.15-9.6% | $463Mvs $483M-4.1% |
Recent stock market news and headlines for Ashland Inc. (ASH)
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro

Key metrics vs top competitors for Ashland Inc. (ASH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $65.73 | $3.01B | -3.58 | -13.68% | -46.33% | -35.41% | 2.51% | |
| $108.28 | $13.87B | 20.24 | 0.51% | 8.63% | 21.79% | — | |
| $81.83 | $20.9B | -56.05 | -5.17% | 7.78% | 5.88% | — | |
| $57.57 | $3.1B | 20.93 | -2.67% | 5.29% | 9.16% | — | |
| $38.10 | $3.49B | 42.81 | 0.61% | 4.81% | 6.6% | — | |
| $168.11 | $5.38B | 35.39 | 8.75% | 14.95% | 12.38% | — |
Ashland Inc. (ASH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ashland Inc. (ASH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 28, 2026·SEC
Feb 2, 2026·SEC
Jan 27, 2026·SEC
Get notified when ASH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ashland Inc. (ASH) stock FAQ — growth, dividends, profitability & financials explained
Ashland Inc. (ASH) reported $1.81B in revenue for fiscal year 2025. This represents a 84% decrease from $11.33B in 1996.
Ashland Inc. (ASH) saw revenue decline by 13.7% over the past year.
Ashland Inc. (ASH) reported a net loss of $706.0M for fiscal year 2025.
Yes, Ashland Inc. (ASH) pays a dividend with a yield of 2.51%. This makes it attractive for income-focused investors.
Ashland Inc. (ASH) has a return on equity (ROE) of -35.4%. Negative ROE indicates the company is unprofitable.
Ashland Inc. (ASH) generated $343.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.